Repinotan, A 5-HT1A Agonist, in the Treatment of Acute Ischemic Stroke

Title: Repinotan, A 5-HT1A Agonist, in the Treatment of Acute Ischemic Stroke

Volume: 4 Issue: 2

Author(s): Helmi L. Lutsep

Affiliation:

Keywords: Infarct, ischemia, acute stroke treatment, neuroprotection, neuroprotectant, repinotan

Abstract: Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5- HT1A agonist BAY x 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.

Cite this article as:

Lutsep L. Helmi, Repinotan, A 5-HT1A Agonist, in the Treatment of Acute Ischemic Stroke, Current Drug Targets - CNS & Neurological Disorders 2005; 4 (2) . https://dx.doi.org/10.2174/1568007053544165